熱門資訊> 正文

ImmunityBio报告第二季度收入高于预期

2025-07-25 18:07

ImmunityBio Inc Ordinary Shares(IBRX) 0
纳比特(NA) 0
盛大科技(SDA) 0

ImmunityBio press release (NASDAQ:IBRX): Q2 revenue of $26.4M (+60.0% Q/Q) beats by $4.45M.

More on ImmunityBio

ImmunityBio: Still Flashing Signs Of Life After Another Anktiva Approval
ImmunityBio: High Stakes On Anktiva's Growth Amidst FDA Friction And Financial Pressures
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
ImmunityBio gets FDA expanded access authorization to treat lymphopenia with Anktiva
ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。